Rwanda President Seeks to Bring First mRNA Vaccine Plant to Africa
(Bloomberg) -- Rwandan President Paul Kagame said his country is in talks to establish the first mRNA vaccine plant in Africa as the continent battles the coronavirus pandemic.
“Rwanda is working with partners to bring the first mRNA manufacturing facility to Africa,” Kagame said at a virtual event this week organized by the Independent Panel for Pandemic Preparedness and Response. He didn't give further details.
Africa has few manufacturing facilities of any kind and most that do exist can only package and distribute the inoculations -- so called fill-finish facilities -- rather than make the ingredients needed for the shots.
mRNA vaccines differ from traditional inoculations in that they use edited messenger RNA, or ribonucleic acid, to protect the body against pathogens. Pfizer Inc., together with BioNTech SE, has developed an mRNA vaccine to fight Covid-19, as has Moderna Inc. Their shots have so far proved more effective than those produced by other companies using more traditional methods.
“I had the opportunity to initiate contacts with different manufacturers of vaccines specifically focusing on the messenger RNA technique used by Moderna and Pfizer,” Kagame said last month. “We have been involved in discussions and I have briefed a few colleagues on our continent but we want to take it forward by discussing it with others.”
To date, only about 20 million Africans out of a continent of 1.3 billion have been vaccinated against Covid-19.
©2021 Bloomberg L.P.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.